WO2012080984A2 - Controlled-release pharmaceutical tablet for oral administration - Google Patents
Controlled-release pharmaceutical tablet for oral administration Download PDFInfo
- Publication number
- WO2012080984A2 WO2012080984A2 PCT/IB2011/055720 IB2011055720W WO2012080984A2 WO 2012080984 A2 WO2012080984 A2 WO 2012080984A2 IB 2011055720 W IB2011055720 W IB 2011055720W WO 2012080984 A2 WO2012080984 A2 WO 2012080984A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral administration
- controlled
- release tablet
- administration according
- polymer
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title claims description 23
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 239000011159 matrix material Substances 0.000 claims abstract description 21
- 238000009792 diffusion process Methods 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 56
- 239000004480 active ingredient Substances 0.000 claims description 30
- 229960003405 ciprofloxacin Drugs 0.000 claims description 27
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 150000007660 quinolones Chemical class 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 230000000979 retarding effect Effects 0.000 claims description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229920001688 coating polymer Polymers 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229960002549 enoxacin Drugs 0.000 claims description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical group N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 2
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003306 fleroxacin Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000497 trovafloxacin Drugs 0.000 claims description 2
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 83
- 238000009472 formulation Methods 0.000 description 43
- 239000013543 active substance Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960003403 betaine hydrochloride Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003754 Atypical mycobacterial infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 208000020426 gonococcal urethritis Diseases 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- -1 polivilpyrrolidone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the present invention relates to modified release pharmaceutical compositions in the form of tablets for oral administration, additionally also relates to the process for the preparation of said compositions.
- the oral administration forms are the most accepted and comfortable for administration.
- Ciprofloxacin is a quinolone derivative that is absorbed quickly in the gastrointestinal tract, so it is desirable to have a pharmaceutical composition that allows the antibiotic to be released in a controlled manner.
- the present invention presents a formulation and a manufacturing process of a modified release drug, with a release profile that allows its administration once a day and that contains at least one active ingredient, for example an antibiotic, such as ciprofloxacin. or other quinolone derivative, as well as its pharmaceutically acceptable salts.
- an antibiotic such as ciprofloxacin. or other quinolone derivative, as well as its pharmaceutically acceptable salts.
- Ciprofloxacin is a broad-spectrum antibiotic, active against Gram-positive and Gram-negative bacteria both in the rapid development phase and in the stationary phase, acting at minimum inhibitory concentrations between 0.01 and 2 mcg / mL. It is useful for treating or preventing bacterial infections of the urinary and respiratory tract, sexually transmitted diseases, septicemia, legionellosis and atypical mycobacteriosis.
- ciprofloxacin can be administered from 500 to 1,500 mg / day, divided into two doses per day for 7 to 14 days. A single dose of 250 mg is recommended in the treatment of uncomplicated gonococcal urethritis.
- modified release compositions of the active ingredient are known for the preparation of modified release compositions of the active ingredient. Frequently it is intended that the composition remains a prolonged time in the stomach to allow adequate absorption In other embodiments, other sections of the gastrointestinal tract may be preferred.
- U.S. Patent Nos. 5,007,790; 5,582,837 and 5,972,389 describe sustained release dosage forms for oral administration, designed to deliver a pharmacologically active agent for a prolonged period of time.
- the active ingredient is dispersed in a plurality of polymeric particles, which have the ability to absorb water, causing swelling.
- the dosage form increases in size, it is prevented from passing through the pylorus into the lower gastrointestinal tract and therefore, the release of the drug takes place in the stomach and in the upper gastrointestinal tract.
- the Mexican patent No. MX 245737 (EP1294363) of Depomed presents an oral dosage form of controlled release comprising: a matrix containing an antibiotic, the matrix has two orthogonal axes of unequal length. After immersion in water, the matrix swells along both axes. The matrix has a shape such that when it is projected on a plane it is an oval or a parallelogram. With this system swallowing of the pharmaceutical form is facilitated and the passage through the pylorus is prevented.
- gastric retention is determined by the degree of swelling of the pharmaceutical form in contact with the aqueous medium.
- a disadvantage of the previously described formulations is that if the pharmaceutical form is divided into two or more fragments before ingesting it, which commonly occurs when the patient finds difficulty at the moment of ingesting the complete pharmaceutical form, gastric retention It will be minimal or nil, and the release of the active ingredient will also be modified.
- the composition of the present invention does not swell during the water immersion process.
- the active principle release control is based on a polymeric matrix and diffusion system, independent of the tablet form.
- Bayer patent MX 243623 offers an oral administration preparation containing a quinolone antibiotic, characterized in that it contains: a) water-swellable polymer and b) a mixture of at least two derivatives of the quinolone antibiotic, which they can be the free base and salt, for example, ciprofloxacin betaine and ciprofloxacin hydrochloride.
- the composition is a two-layer tablet containing: a quick-release part, which may contain the salt and base mixture free of ciprofloxacin, disintegrant (eg PVP) and excipients, as well as another delayed-release part that may contain the mixture of salt and ciprofloxacin free base, retardant polymer (for example, low viscosity polymer such as HPMC (hydroxypropyl methylcellulose)), organic acid (for example, succinic acid) and excipients.
- a quick-release part which may contain the salt and base mixture free of ciprofloxacin, disintegrant (eg PVP) and excipients, as well as another delayed-release part that may contain the mixture of salt and ciprofloxacin free base, retardant polymer (for example, low viscosity polymer such as HPMC (hydroxypropyl methylcellulose)), organic acid (for example, succinic acid) and excipients.
- retardant polymer for example, low viscosity polymer such
- the composition of the present invention allows to obtain a release of active ingredient both fast and modified, and the release is not affected if the pharmaceutical form is divided before ingestion.
- Another disadvantage of the composition, MX 243623 patent is that both ciprofloxacin betaine and ciprofloxacin hydrochloride are used. It is well known that the basic form of ciprofloxacin is more unstable than salt, so that a stabilizing agent is required. In contrast, the composition of the present invention does not necessarily require a stabilizing agent, since more stable forms of the active ingredient, such as a ciprofloxacin salt, can be used. This allows to reduce operating times and costs.
- Patent document MX / a / 2001/002634 offers an oral controlled release formulation in tablets containing an effective amount of ciprofloxacin base, and approximately 0.2% to 0.5% sodium alginate , 0.5% to 2.0% xanthan gum, 25% sodium bicarbonate as a gas generating agent and 20% of polyvinylpyrrolidone.
- This controlled release formulation is swollen by the effect of sodium bicarbonate and sodium alginate. Upon swelling, the tablet is retained in the lower part of the stomach and before passing through the pylorus, thereby achieving a controlled release of ciprofloxacin at the site of absorption.
- Patent document MX / a / 2002/008568 offers an oral formulation of controlled release in tablets for administration once a day, which contains an effective amount of ciprofloxacin base and a viscolizing agent (also called viscous agent) ), a carboxylic or cellulose gum, gelling agent (also called gelling agent) sodium alginate, gas generating agent (carbonate or sodium bicarbonate) and a swelling agent (crosslinked polyvinyl pyrrolidone).
- a viscolizing agent also called viscous agent
- carboxylic or cellulose gum also called gelling agent
- gelling agent also called gelling agent
- gas generating agent carbonate or sodium bicarbonate
- swelling agent crosslinked polyvinyl pyrrolidone
- the present invention presents a modified release formulation comprising an active ingredient, but not limited to, a derivative of Quinolone as ciprofloxacin hydrochloride, without the inclusion of gas-generating agents or gelling networks, which makes it not an inflatable formulation. Instead, there is a polymeric matrix system for diffusion of the active substance, which complies with a release profile for administration once a day. For this, excipients are used that delay the release of the active ingredient, coated by a matrix polymeric that in contact with the gastric medium is eroded to form a plurality of channels through which the active substance is released by diffusion.
- the present invention relates to a modified release composition, which represents an advantage at the time of administration since greater adherence to the treatment regimen is achieved, the administration of the medicament being once a day for the required period. JUSTIFICATION OF THE INVENTION.
- compositions that offer controlled release formulations of active ingredient, however, all of them are obtained through processes made with the use of a large number of excipients.
- the present invention offers a combination of systems that allow obtaining a composition that allows to achieve a controlled release profile, and that in a preferred embodiment the release is modified tangentially, using a smaller amount of excipients and using a smaller amount of inputs, time and labor during the preparation of the composition.
- Another innovation of the composition is the use of a barrier-diffuser matrix with a double function: taste masking and diffusion barrier.
- Figure 1 shows the plasma level curves against the absorption time of the formulation of the present invention (Graph with white circuits) compared to a reference formulation (commercial product, Bayer's Cipro XR®, inflatable tablet) (Graph with black circuits).
- the challenge faced by the development of the present invention is to obtain an oral pharmaceutical composition, which complies with the required release profile of the active ingredient and that in a preferred embodiment the release is modified tangentially, for administration once daily, where the resulting composition is stable, safe and with therapeutic efficacy.
- composition of the present invention offers a combination of systems that makes it possible to obtain modified tangential release of the active ingredient, using a smaller amount of excipients and using a smaller amount of inputs, time and labor during the preparation of the composition.
- a polymeric matrix release system that doses the active ingredient in two continuous phases at two different rates in the same dose unit.
- This system consists of an internal part of delayed release, and an external part of rapid release.
- the delayed-release part contains the active substance and excipients that give it protection and allow it to delay the release of ciprofloxacin abroad.
- it is exposed to the active principle by a two-way controlled release: diffusion through a polymeric matrix and release through the channels formed by erosion of a polymeric matrix.
- the combination of these release processes results in an active principle release process in a modified and controlled manner.
- composition within the organism exhibits a release suitable for oral administration once a day by combining diffusion and erosion systems.
- compositions of easy swallowing and with modified release systems wherein the active ingredient is included in amounts equal to or greater than 500mg.
- a such a high amount of active ingredient would imply the use of a large number of excipients.
- a tablet is obtained that allows it to be more accepted by the patient who has swallowing problems, stable, safe, which allows masking the unpleasant taste of ciprofloxacin.
- the active ingredient comprises about 80% by weight of the formulation and the excipients about 20%.
- the components of the formulation are:
- Active ingredient the active substance is selected from any drug that is required to be administered in a modified and / or delayed manner, this may be a quinolone derivative such as ciprofloxacin or pharmaceutically acceptable salts thereof.
- Binder diluent it can be selected from microcrystalline cellulose, polivilpyrrolidone, hydroxypropyl methylcellulose, lactose, starch, calcium dibasic phosphate, mixture thereof or other equivalent excipient. Microcrystalline cellulose is preferred. This excipient is in the formulation in a range of 10% to 20% by weight and in a preferred embodiment is between 10% to 15% by weight.
- Retardant polymer selected from ethyl cellulose, oleic oil, derivatives of the copolymer of methacrylic acid, cellulose acetate, methyl cellulose. This excipient is found in the formulation in a range of 0.5 to 6% by weight and in a preferred embodiment is between 3% to 6% by weight.
- Matrix forming polymer selected from HPMC (hydroxypropyl methylcellulose or hypromellose), hydroxyethylcellulose, hydroxymethylcellulose, methylcellulose, derived from methacrylate acid copolymers. This component is in the formulation in a range of 0.5 to 10% by weight and in a preferred embodiment is between 5% to 10% by weight.
- Diluent or diluent agent can be selected from: lactose monohydrate, microcrystalline cellulose, dextrose, sucralose or sucrose and / or mannitol.
- Sliding is selected from magnesium stearate, magnesium phosphate, stearic acid, glyceryl stearate, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, talc, mixture thereof or other equivalent excipient.
- Coating polymer can be selected from cellulose and methacrylate derivatives, polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl methylcellulose, carrageenan or any other equivalent excipient.
- Table 1 illustrates three examples of formulations obtained during the development of the present invention. TABLE 1
- HPMC is hydroxypropyl methylcellulose and PM means molecular weight
- Critical excipients in the present formulation are the "retarding polymer” and the "matrix forming polymer.”
- HPMC high molecular weight polymers are recommended by manufacturers of excipients for modified release, however, it was observed that when using these high molecular weight polymers as matrix formers in With ciprofloxacin formulations, a considerable delay of the release is obtained and therefore the active principle is not released in the times to comply with the specification.
- HPMC 5 of very low molecular weight does allow the release at specified times.
- Tablet formulations in the form of coated tablets were evaluated with stability studies to verify that they are robust and compliant formulations and They retain their stability.
- Table 3 shows the results of a stability test for formulation 3, which shows that under different conditions it retains the characteristics of being an oblong, homogeneous and smooth tablet.
- Table 4 shows the general tablet formulation in the form of tablets, according to formulation 3.
- a preferred formulation without limiting the scope of the present invention is that which contains from 250 mg to 1500 mg of active ingredient.
- Tablet formulations in the form of coated tablets can be made without limiting the scope of the present invention in presentations containing from 250mg, 500mg, 750mg, lOOOmg and up to 1500mg of ciprofloxacin, some examples are shown in Table 5.
- excipients used do not represent more than 20% of the weight of the formulation. Through a careful selection of excipients a formulation was achieved that allows using the least amount of them. This is because the matrix forming polymer and the retarding polymer have a double function. The matrix forming polymer is also a taste masking. The polymer that delays the release of the active ingredient also acts as a lubricant with good flow properties, which obviously results in a reduction in operating times and material supply costs.
- Granular hypromellose, the active substance and water (granulate 2).
- the obtained tablet is placed in the coater where it is sprayed with the final protective cover.
- the finished product is conditioned.
- the formulations obtained do not limit the content of the active ingredients to the formulations presented as examples, since they can be presented with any other active ingredient capable of being integrated into the formulation.
- the active ingredients used are derivatives of quinolones selected from enoxacin, ofloxacin, norfloxacin, ciprofloxacin, levofloxacin, fleroxacin, perfloxacin, trovafloxacin and their pharmaceutically acceptable salts or hydrates.
- the present invention provides oral pharmaceutical compositions comprising an active ingredient, such as a quinolone derivative, or its pharmaceutically acceptable salts or hydrates, from 500 mg to 1000 mg even up to 1,500 mg in one same dose unit, without compromising the controlled release of the composition.
- an active ingredient such as a quinolone derivative, or its pharmaceutically acceptable salts or hydrates
- a Bioequivalence Study of the composition was carried out to know the concentration, time of release of the active substance ciprofloxacin or its acceptable pharmaceutical salts, in its healthy etho-volunteers.
- a cross-sectional study was carried out two sequences, two periods (2x2) at a therapeutic dose of 1 g of ciprofloxacin contained in a dose unit (tablet).
- Plasma samples were processed through the liquid-liquid extraction technique and ciprofloxacin concentrations were determined by the High Resolution Liquid Chromatography Method.
- Figure 1 shows the plasma level curves of the formulation of the present invention (white circles) and a reference formulation (black circles). This figure shows that the formulation of the present invention meets the required characteristics such as a release greater than 40% in the first hour and greater than 80% after 4 hours.
- composition of the present invention once-daily extended-release tablet, is bioequivalent with the reference formulation, but the advantage that only one ciprofloxacin derivative is used and that the release of the active substance is independent of the swelling of the pharmaceutical form.
- composition of the present invention is that it is effective and safe in its administration.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112013014963A BR112013014963A2 (en) | 2010-12-17 | 2011-12-16 | controlled release pharmaceutical tablet for oral administration |
RU2013127408/15A RU2603469C2 (en) | 2010-12-17 | 2011-12-16 | Controlled-release pharmaceutical tablet for oral administration methods for preparation thereof |
CR20130288A CR20130288A (en) | 2010-12-17 | 2013-06-13 | COMPRESSED PHARMACEUTICAL CONTROLLED RELEASE FOR ORAL ADMINISTRATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010014153A MX2010014153A (en) | 2010-12-17 | 2010-12-17 | Controlled-release pharmaceutical tablet for oral administration. |
MXMX/A/2010/014153 | 2010-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012080984A2 true WO2012080984A2 (en) | 2012-06-21 |
WO2012080984A3 WO2012080984A3 (en) | 2012-08-16 |
Family
ID=46245166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/055720 WO2012080984A2 (en) | 2010-12-17 | 2011-12-16 | Controlled-release pharmaceutical tablet for oral administration |
Country Status (11)
Country | Link |
---|---|
BR (1) | BR112013014963A2 (en) |
CL (1) | CL2013001707A1 (en) |
CO (1) | CO6721021A2 (en) |
CR (1) | CR20130288A (en) |
DO (1) | DOP2013000136A (en) |
EC (1) | ECSP13012766A (en) |
GT (1) | GT201300154A (en) |
MX (1) | MX2010014153A (en) |
PE (1) | PE20140675A1 (en) |
RU (1) | RU2603469C2 (en) |
WO (1) | WO2012080984A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016058813A1 (en) | 2014-10-16 | 2016-04-21 | Koninklijke Philips N.V. | Aligning a patient within an mr scanner |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035177A2 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
WO2003053402A1 (en) * | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL119627A (en) * | 1996-11-17 | 2002-03-10 | Yissum Res Dev Co | PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT |
-
2010
- 2010-12-17 MX MX2010014153A patent/MX2010014153A/en active IP Right Grant
-
2011
- 2011-12-16 RU RU2013127408/15A patent/RU2603469C2/en active
- 2011-12-16 BR BR112013014963A patent/BR112013014963A2/en not_active Application Discontinuation
- 2011-12-16 WO PCT/IB2011/055720 patent/WO2012080984A2/en active Application Filing
- 2011-12-16 PE PE2013001406A patent/PE20140675A1/en active IP Right Grant
-
2013
- 2013-06-13 CL CL2013001707A patent/CL2013001707A1/en unknown
- 2013-06-13 CR CR20130288A patent/CR20130288A/en unknown
- 2013-06-14 DO DO2013000136A patent/DOP2013000136A/en unknown
- 2013-06-17 GT GT201300154A patent/GT201300154A/en unknown
- 2013-06-18 CO CO13145004A patent/CO6721021A2/en unknown
- 2013-07-15 EC ECSP13012766 patent/ECSP13012766A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035177A2 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
WO2003053402A1 (en) * | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
Non-Patent Citations (1)
Title |
---|
DATABASE HCAPLUS CHEMICAL ABSTRACTS SERVICE STN Database accession no. 2008:104222 & PEI, ZHI-GIANG ET AL.: 'Optimization of levofloxacin hydrochloride sustained-release tablets by central composite design' YAOXUE JINZHAN vol. 31, no. 11, 2007, ISSN 1001-5094 pages 508 - 512 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016058813A1 (en) | 2014-10-16 | 2016-04-21 | Koninklijke Philips N.V. | Aligning a patient within an mr scanner |
Also Published As
Publication number | Publication date |
---|---|
CO6721021A2 (en) | 2013-07-31 |
RU2603469C2 (en) | 2016-11-27 |
MX2010014153A (en) | 2012-06-18 |
BR112013014963A2 (en) | 2016-09-13 |
DOP2013000136A (en) | 2013-10-15 |
PE20140675A1 (en) | 2014-06-25 |
CR20130288A (en) | 2013-08-13 |
RU2013127408A (en) | 2015-01-27 |
ECSP13012766A (en) | 2013-09-30 |
WO2012080984A3 (en) | 2012-08-16 |
CL2013001707A1 (en) | 2014-01-10 |
GT201300154A (en) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2205454T3 (en) | FORMULATIONS OF CLARITROMYCIN OF PROLONGED RELEASE. | |
ES2525005T3 (en) | Extended release formulation containing a wax | |
ES2663135T3 (en) | Deferasirox oral formulations | |
ES2663744T3 (en) | Pharmaceutical compositions comprising 40-O- (2-hydroxy) ethyl-rapamycin | |
ES2281313T3 (en) | Pharmaceutical compositions comprising lercanidipine | |
JP2018500353A (en) | Ileum-jejunum drug delivery composition | |
ES2320847T3 (en) | Improved lamotrigine formulations | |
ES2303255T3 (en) | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS. | |
BRPI0608853B1 (en) | pharmaceutical compositions and process for the manufacture of gastro-resistant rifaximin microgranules | |
AU2010211980A1 (en) | Dual release pharmaceutical suspension | |
KR101269829B1 (en) | Sustained release preparation using gastric retentive drug delivery system | |
ES2616115T3 (en) | Oral controlled release pharmaceutical form comprising oxycodone | |
KR102479497B1 (en) | Sustained release pharmaceutical formulation of varenicline and preparation method thereof | |
ES2336215T3 (en) | PHARMACEUTICAL COMPOSITIONS OF MODAFINIL WITH MODIFIED RELEASE. | |
AU2018285927B2 (en) | Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders | |
KR20150002453A (en) | Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof | |
WO2014104929A1 (en) | Pharmaceutical composition for treatment of hiv infections | |
KR101093781B1 (en) | Solid pharmaceutical composition of moxifloxacin comprising ph adjustment agent | |
WO2012080984A2 (en) | Controlled-release pharmaceutical tablet for oral administration | |
US20170312224A1 (en) | Extended release formulations of flurbiprofen and tramadol | |
ES2953126T3 (en) | A method for manufacturing a pharmaceutical composition comprising Nefopam and Acetaminophen, and the pharmaceutical composition obtained in this way | |
US20170312236A1 (en) | Pharmaceutical compositions of flurbiprofen and tramadol | |
WO2017029225A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
ES2862209T3 (en) | Solid non-pulsatile prolonged-release oral compositions containing betahistine | |
ES2643287T3 (en) | Lacosamide oral disintegration formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2013001707 Country of ref document: CL Ref document number: 001406-2013 Country of ref document: PE Ref document number: CR2013-000288 Country of ref document: CR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13145004 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2013127408 Country of ref document: RU Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11848659 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013014963 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013014963 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130614 |